Unveiling the impact of DNA-methylation age acceleration on mortality risk in diabetes and pre-diabetes: insights from the US NHANES program
Abstract Background Diabetes ranks as the ninth leading cause of death globally, and DNA-methylation age acceleration (DNAmAA) is closely linked to lifespan. However, the impact of DNAmAA on long-term outcomes in specific populations with diabetes and pre-diabetes has not yet been comprehensively st...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Clinical Epigenetics |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13148-025-01886-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849309712653221888 |
|---|---|
| author | Shuang Wu Ziyi Zhong Yimeng Wang Jingyang Wang Siqi Lyu Hongyu Liu Yang Chen |
| author_facet | Shuang Wu Ziyi Zhong Yimeng Wang Jingyang Wang Siqi Lyu Hongyu Liu Yang Chen |
| author_sort | Shuang Wu |
| collection | DOAJ |
| description | Abstract Background Diabetes ranks as the ninth leading cause of death globally, and DNA-methylation age acceleration (DNAmAA) is closely linked to lifespan. However, the impact of DNAmAA on long-term outcomes in specific populations with diabetes and pre-diabetes has not yet been comprehensively studied. Methods This retrospective cohort study utilized data from the National Health and Nutrition Examination Survey (NHANES) 1999–2002, including participants aged 20 years or older diagnosed with diabetes or pre-diabetes. DNAmAA was defined as the difference between epigenetic age and chronological age. Multiple generations of DNAmAA measures were included. Cox proportional hazards regression models were employed to estimate the associations between DNAmAAs and all-cause, cardiovascular, and non-cardiovascular mortality. Results A total of 1,199 participants were included, with a mean age of 64.20 (0.46) years; 621 (51.8%) were male. Significant correlations were observed between chronological age and all DNA-methylation ages in both diabetes and pre-diabetes groups. Over a mean follow-up of 14.13 (5.90) years, 662 deaths were recorded. AgeAccelGrim2 exhibited the strongest association with mortality. Each 5-unit increase in AgeAccelGrim2 was associated with an elevated risk of all-cause mortality (HR 1.35, 95% CI 1.23–1.49), cardiovascular mortality (HR 1.50, 95% CI 1.25–1.80), and non-cardiovascular mortality (HR 1.30, 95% CI 1.16–1.46). These associations remained significant in participants with diabetes and pre-diabetes. Mediation analysis revealed that AgeAccelGrim2 significantly mediates the association between health-related exposures (including the Oxidative Balance Score, Life’s Simple 7 score, and frailty score) and all-cause mortality in diabetes and pre-diabetes populations. Conclusions AgeAccelGrim2 could serve as a valuable biomarker for mortality risk specific to populations with diabetes and pre-diabetes, offering potential applications in personalized management strategies and risk stratification. |
| format | Article |
| id | doaj-art-401e2d87ad204abdbec5a3c460e1a38f |
| institution | Kabale University |
| issn | 1868-7083 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Clinical Epigenetics |
| spelling | doaj-art-401e2d87ad204abdbec5a3c460e1a38f2025-08-20T03:53:58ZengBMCClinical Epigenetics1868-70832025-05-0117111310.1186/s13148-025-01886-0Unveiling the impact of DNA-methylation age acceleration on mortality risk in diabetes and pre-diabetes: insights from the US NHANES programShuang Wu0Ziyi Zhong1Yimeng Wang2Jingyang Wang3Siqi Lyu4Hongyu Liu5Yang Chen6National Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeLiverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest HospitalNational Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeNational Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeNational Center for Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeLiverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest HospitalLiverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest HospitalAbstract Background Diabetes ranks as the ninth leading cause of death globally, and DNA-methylation age acceleration (DNAmAA) is closely linked to lifespan. However, the impact of DNAmAA on long-term outcomes in specific populations with diabetes and pre-diabetes has not yet been comprehensively studied. Methods This retrospective cohort study utilized data from the National Health and Nutrition Examination Survey (NHANES) 1999–2002, including participants aged 20 years or older diagnosed with diabetes or pre-diabetes. DNAmAA was defined as the difference between epigenetic age and chronological age. Multiple generations of DNAmAA measures were included. Cox proportional hazards regression models were employed to estimate the associations between DNAmAAs and all-cause, cardiovascular, and non-cardiovascular mortality. Results A total of 1,199 participants were included, with a mean age of 64.20 (0.46) years; 621 (51.8%) were male. Significant correlations were observed between chronological age and all DNA-methylation ages in both diabetes and pre-diabetes groups. Over a mean follow-up of 14.13 (5.90) years, 662 deaths were recorded. AgeAccelGrim2 exhibited the strongest association with mortality. Each 5-unit increase in AgeAccelGrim2 was associated with an elevated risk of all-cause mortality (HR 1.35, 95% CI 1.23–1.49), cardiovascular mortality (HR 1.50, 95% CI 1.25–1.80), and non-cardiovascular mortality (HR 1.30, 95% CI 1.16–1.46). These associations remained significant in participants with diabetes and pre-diabetes. Mediation analysis revealed that AgeAccelGrim2 significantly mediates the association between health-related exposures (including the Oxidative Balance Score, Life’s Simple 7 score, and frailty score) and all-cause mortality in diabetes and pre-diabetes populations. Conclusions AgeAccelGrim2 could serve as a valuable biomarker for mortality risk specific to populations with diabetes and pre-diabetes, offering potential applications in personalized management strategies and risk stratification.https://doi.org/10.1186/s13148-025-01886-0DNA-methylation ageDNA-methylation age accelerationGrimAge2MortAgeAccelGrim2DiabetesPre-diabetes |
| spellingShingle | Shuang Wu Ziyi Zhong Yimeng Wang Jingyang Wang Siqi Lyu Hongyu Liu Yang Chen Unveiling the impact of DNA-methylation age acceleration on mortality risk in diabetes and pre-diabetes: insights from the US NHANES program Clinical Epigenetics DNA-methylation age DNA-methylation age acceleration GrimAge2Mort AgeAccelGrim2 Diabetes Pre-diabetes |
| title | Unveiling the impact of DNA-methylation age acceleration on mortality risk in diabetes and pre-diabetes: insights from the US NHANES program |
| title_full | Unveiling the impact of DNA-methylation age acceleration on mortality risk in diabetes and pre-diabetes: insights from the US NHANES program |
| title_fullStr | Unveiling the impact of DNA-methylation age acceleration on mortality risk in diabetes and pre-diabetes: insights from the US NHANES program |
| title_full_unstemmed | Unveiling the impact of DNA-methylation age acceleration on mortality risk in diabetes and pre-diabetes: insights from the US NHANES program |
| title_short | Unveiling the impact of DNA-methylation age acceleration on mortality risk in diabetes and pre-diabetes: insights from the US NHANES program |
| title_sort | unveiling the impact of dna methylation age acceleration on mortality risk in diabetes and pre diabetes insights from the us nhanes program |
| topic | DNA-methylation age DNA-methylation age acceleration GrimAge2Mort AgeAccelGrim2 Diabetes Pre-diabetes |
| url | https://doi.org/10.1186/s13148-025-01886-0 |
| work_keys_str_mv | AT shuangwu unveilingtheimpactofdnamethylationageaccelerationonmortalityriskindiabetesandprediabetesinsightsfromtheusnhanesprogram AT ziyizhong unveilingtheimpactofdnamethylationageaccelerationonmortalityriskindiabetesandprediabetesinsightsfromtheusnhanesprogram AT yimengwang unveilingtheimpactofdnamethylationageaccelerationonmortalityriskindiabetesandprediabetesinsightsfromtheusnhanesprogram AT jingyangwang unveilingtheimpactofdnamethylationageaccelerationonmortalityriskindiabetesandprediabetesinsightsfromtheusnhanesprogram AT siqilyu unveilingtheimpactofdnamethylationageaccelerationonmortalityriskindiabetesandprediabetesinsightsfromtheusnhanesprogram AT hongyuliu unveilingtheimpactofdnamethylationageaccelerationonmortalityriskindiabetesandprediabetesinsightsfromtheusnhanesprogram AT yangchen unveilingtheimpactofdnamethylationageaccelerationonmortalityriskindiabetesandprediabetesinsightsfromtheusnhanesprogram |